secwatch / observer
8-K filed November 8, 2022, 6:59 PM ET ticker SGRY CIK 0001638833
earnings confidence high sentiment positive materiality 0.75

Surgery Partners Q3 revenue +11% to $620.6M, Adj EBITDA $96.2M, reaffirms FY guidance

Surgery Partners, Inc.

2022-Q3 EPS reported -$0.35 revenue$1,832,200,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Surgery Partners, Inc. reported Full year 2022 results: revenue $2.5 billion to $2.55 billion. Guidance reaffirmed.

Period
Full year 2022
Revenue
$2.5 billion to $2.55 billion
Guidance
reaffirmed
Result
guidance update
Exact text from the filing
The Company reaffirms projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Surgery Partners, Inc. reported Third quarter ended September 30, 2022 results: revenue $620.6 million, net income -$25.0 million.

Period
Third quarter ended September 30, 2022
Revenue
$620.6 million
Net income
-$25.0 million
Result
reported results
Exact text from the filing
Revenue for the third quarter of 2022 increased 11.0% to $620.6 million from $559.2 million for the third quarter of 2021. Same-facility revenues for the third quarter of 2022 increased 5.1% from the same period last year, with an increase in revenue per case of 1.8% and an increase in same-facility cases of 3.3%. For the third quarter of 2022, the Company’s net 1 loss attributable to common stockholders and Adjusted EBITDA was $25.0 million and $96.2 million, respectively, compared to $22.9 million and $76.4 million, respectively, for the same period last year.
View on SEC.gov

Browse all earnings releases →

Surgery Partners, Inc. filing history →

Source: SEC EDGAR
accession 0001638833-22-000132
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.